Prosigna Breast Risk of Recurrence Test

The Prosigna test enables a comprehensive result to accurately measure the risk of recurrence in a complex decision-making process. 

Learn More Contact Us
Cancer area illustration

Proven Prognostic Accuracy

What is the Prosigna Breast test?

The Prosigna Breast Risk of Recurrence test combines intrinsic molecular subtypes and proliferation score with clinical pathological factors into a single 10-year Risk of Recurrence (ROR) score.

These results help clinicians make informed and personalized treatment decisions for their patients with early-stage, hormone receptor positive (HR+), breast cancer. 

Inherited Risk Assessment
Screening and Risk Assessment
Diagnosis
Prognosis
Treatment Guidance
Recurrence Monitoring

I knew there was another genomic test that could provide this information, but I specifically requested the Prosigna test because I wanted to be sure of the accuracy for guiding my treatment decisions.”1

Joyce D., 72 Diagnosed with invasive breast cancer. Her Prosigna score gave her the confidence to choose endocrine therapy alone.

Talk to your doctor about whether Veracyte tests might be right for you.

The breast cancer landscape

Statistics

Globally, breast cancer remains the most common cancer among women.2

  • Breast cancer affects 1 in 83 women in the United States and 1 in 122 women globally.
  • In the US, an estimated 321,910 women and 2,670 men will be diagnosed with invasive breast cancer in 2026.3
  • Among these patients, about 70% will be diagnosed with hormone receptor-positive (HR+) breast cancer.4

Challenges

Choosing the best treatment path is paramount to preventing cancer from coming back.

When breast cancer is caught early, and treated appropriately, there is a 91% 5-year survival rate.3 However, it can recur up to 20 years later.5 Survival after a distant metastatic recurrence is significantly lower and dependent on the subtype of the cancer.6



Genomic testing helps identify patients who may safely avoid chemotherapy – and its toxic long term side effects – while maintaining strong chances of remaining breast cancer-free.  

Keep exploring

Clinical Studies

Studies demonstrating the impact of our tests across cancer types.

Discover

Scientific Publications

Veracyte publications and references showcasing discoveries and advancements.

Explore

Resource Center

View scientific publications, videos, FAQS, and more.

Explore

Events

Meet with us and discuss how we support clinicians.

Learn More

Connect with us

Contact Us

References

  1. Veracyte, Inc. Company data on file. Updated March 2026.
  2. https://www.wcrf.org/preventing-cancer/cancer-statistics/breast-cancer-statistics/
  3. https://www.nationalbreastcancer.org/breast-cancer-facts/ 
  4. https://seer.cancer.gov/statfacts/html/breast-subtypes.html 
  5. https://www.bcrf.org/about-breast-cancer/breast-cancer-recurrence/
  6. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/2024/breast-cancer-facts-and-figures-2024.pdf

Disclaimers

The Prosigna Breast Cancer Prognostic Gene Signature Assay is available as a CE-IVD test outside the US. To find out if Prosigna is available in your country or for information about reimbursement and insurance coverage, contact us at [email protected].

This site is registered on wpml.org as a development site. Switch to a production site key to remove this banner.